Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 97, Issue -, Pages 204-236Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2015.11.011
Keywords
Hyaluronic acid; Drug delivery systems; Nanotechnology; CD44; Conjugates; Anticancer agents
Categories
Funding
- MIUR-University of Torino Fondi Ricerca Locale
- Galileo project University Italo-Francese
Ask authors/readers for more resources
Hyaluronic acid (HA) is widely used in anticancer drug delivery, since it is biocompatible, biodegradable, nontoxic, and non-immunogenic; moreover, HA receptors are overexpressed on many tumor cells. Exploiting this ligand-receptor interaction, the use of HA is now a rapidly-growing platform for targeting CD44-overexpressing cells, to improve anticancer therapies. The rationale underlying approaches, chemical strategies, and recent advances in the use of HA to design drug carriers for delivering anticancer agents, are reviewed. Comprehensive descriptions are given of HA-based drug conjugates, particulate carriers (micelles, liposomes, nanopartides, microparticles), inorganic nanostructures, and hydrogels, with particular emphasis on reports of preclinical/clinical results. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available